A Multi-phase Dose-Escalation followed by an Open-label Randomized Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects with Myelodysplastic Syndromes (MDS) Chronic Myelomonocy

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Myelodysplastic Syndromes (mds), Chronic Myelomonocytic Leukemia (cmml), Or Acute Myeloid Leukemia (aml)
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Confirmed MDS, CMML, and other MDS/MPN or AML who will benefit from taking oral ASTX030
    2. Proper kidney and liver organ function
    3. No major surgery within 2 weeks before first study treatment

You may not be eligible for this study if the following are true:

    1. A stomach or small intestine sore that is not under control
    2. Other sicknesses that are not controlled or have infections caused by bacteria, viruses, or fungi that are not controlled; it might be too risky for your health, interfere

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.